Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T3635 |
IQ 1
IQ1,IQ-1 |
Wnt/beta-catenin | Cytoskeletal Signaling; Stem Cells |
IQ 1 有多种作用,如保持小鼠ESCs 的多功能性、降低Wnt 刺激的磷酸化、阻止PP2A/Nkd 的相互作用等等。 | |||
TP2110L |
TAT-Gap19 acetate
|
Gap Junction Protein | Cytoskeletal Signaling |
TAT-Gap19 acetate 是 connexin43 hemichannel (Cx43 HC) 的特异性抑制剂。 它穿过血脑屏障并减轻小鼠的肝纤维化。它不抑制相应的 Cx43 GJC。 | |||
TP1563 |
Gap19
|
Gap Junction Protein | Cytoskeletal Signaling |
Gap19 是一种衍生自 Cx43 细胞质环九个氨基酸的肽,是选择性连接蛋白 43 半通道阻滞剂。它可以防止 C 末端与 CL 的分子内相互作用,具有保护心肌作用。 | |||
T3983 |
TMP195
TFMO 2,TMP 195 |
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
TMP195 (TFMO 2) 是一种选择性 IIa 类组蛋白脱乙酰酶 (HDAC) 抑制剂。对 HDAC4、HDAC5、HDAC7,HDAC9的 Ki 值分别为59、60、26,5 nM。 | |||
T75821 |
TAT-Gap19 TFA
|
||
TAT-Gap19 TFA为Cx模拟肽,特异性抑制connexin43半通道(Cx43 HC),但不影响相应的Cx43 GJC。该化合物具备透过血脑屏障功能,能够减轻小鼠肝纤维化。 | |||
TP1511 |
Gap19 TFA (1507930-57-5 free base)
Gap19 TFA |
||
Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker. | |||
TP2110 |
TAT-Gap19
|
||
Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penet | |||
T75820 |
Gap19 TFA
|
||
Gap19 TFA,源自Cx43胞浆环(CL)的九个氨基酸肽,是高效且选择性的连接蛋白43 (Cx43) 半通道阻滞剂。该肽阻止C末端(CT)与CL之间的分子内相互作用,但不影响GJ通道或Cx40/pannexin-1半通道。此外,Gap19 TFA对心肌有保护作用。 | |||
T73571 |
CP19
|
Others | Others |
CP19, 作为一种组胺受体(histamine receptor)拮抗剂,展现出针对埃博拉病毒(EBOV)及马尔堡病毒(MARV)的进入抑制活性,其IC50值对EBOV为3.4 μM,对MARV为29.5 μM。该化合物针对EBOV和MARV的SI值分别达到29.4及3.4,表明CP19具备显著的抗病毒效能。 | |||
T41204 |
TAT-Gap19(I130A)
TAT-Gap19(I130A) |
Others | Others |
TAT-Gap19(I130A) is a control peptide for TAT-Gap19, a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable. | |||
T76273 |
Pep19-2.5
|
||
Pep19-2.5为合成抗毒素肽,能阻断内毒素信号级联。通过抑制跨膜及胞质模式识别受体(PRRs)介导的脂肽(LP)与脂多糖(LPS)的信号通路,Pep19-2.5关键调控与炎症及细胞焦亡(pyroptosis)相关的信号级联。 | |||
T36900 |
PD-1/PD-L1-IN-NP19
PD-1/PD-L1-IN-NP19 |
PD-1/PD-L1 | Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation |
PD-1/PD-L1-IN-NP19 是 PD-1/PD-L1 的抑制剂,抑制人类 PD-1/PD-L1 相互作用的 IC50 值为 12.5 nM。PD-1/PD-L1-IN-NP19 可以激活肿瘤的免疫微环境,这可能有助于其抗肿瘤作用。 | |||
T76784 |
Tildrakizumab
MK 3222,SCH 900222 |
IL Receptor | Immunology/Inflammation |
Tildrakizumab (SCH 900222) 是一种有效的人源化抗-IL-23 (p19 亚基) 单克隆抗体。Tildrakizumab 靶向单链 IL-23 ,Kd 值为 136 pM。Tildrakizumab 可用于研究银屑病和牛皮癣。 | |||
T76778 |
Risankizumab
Risankizumab rzaa,SKYRIZI,ABBV 066,BI-655066 |
IL Receptor | Immunology/Inflammation |
Risankizumab (BI 655066) 是一种人源化靶向 IL-23 p19 亚基的 IgG 单克隆抗体(Kd <10 pM)。 Risankizumab 能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生,IC50 值为 2 pM。Risankizumab 可用于预防和治疗如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病类的免疫性和炎症性疾病。 | |||
T33652 |
Neurodazole
|
Others | Others |
Neurodazole is a neurogenic inducer for converting pluripotent P19 cells into electrophysiologically active neurons. | |||
T77088 | Mirikizumab | ||
Mirikizumab (LY3074828),一种靶向白介素23的p19亚基的人源化IgG4单克隆抗体,适用于溃疡性结肠炎的研究。 | |||
T61858 |
HDAC8-IN-3
|
Others | Others |
HDAC8-IN-3 (compound P19) is a highly potent inhibitor of HDAC8, displaying an IC50 value of 9.3 μM and producing thermal stabilization. Moreover, HDAC8-IN-3 exhibits cytotoxicity and induces apoptosis specifically in leukemic cell lines [1]. | |||
T76934 |
Brazikumab
|
||
Brazikumab (AMG 139) 是一种人IgG2单克隆抗体,可选择性结合IL-23的 p19 亚基,对人IL-23的KD 值为 0.138 nM 的。Brazikumab 可用于克罗恩病的研究。 |